Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 17/20 | 0.62 |
| ▸ | THRA | P10827 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124459 | 0.87 | PCNA (0.76) | PCNATHRATHRBRXRAPPARG | |
| SCHEMBL5742010 | 0.87 | PCNA (0.57) | PCNATHRATHRBRXRAPPARG | |
| SCHEMBL5743354 | 0.87 | PCNA (0.54) | PCNATHRATHRBRXRAPPARG | |
| SCHEMBL14484569 | 0.85 | PCNA (0.62) | PCNATHRATHRBRXRAPPARG | |
| SCHEMBL5742613 | 0.84 | PCNA (0.74) | PCNATHRATHRBRXRAPPARG | |
| SCHEMBL5742819 | 0.83 | TAAR5 (0.59) | PCNAPPARGCYP1A2SMN1; SMN2HIF1A | |
| SCHEMBL5741869 | 0.83 | PCNA (0.62) | PCNATHRATHRBRXRAPPARG | |
| SCHEMBL16124453 | 0.83 | PCNA (0.78) | PCNATHRATHRBRXRAPPARG | |
| SCHEMBL4004003 | 0.79 | PCNA (0.58) | PCNALIG1 | |
| SCHEMBL16124460 | 0.79 | PCNA (0.76) | PCNATHRATHRBRXRAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383729-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | claimed |
| US-20040267015-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-12-30 | — | — | US | claimed |
| EP-1383729-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002081426-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1383729-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20040267015-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1383729-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002081426-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267015-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | PCNA 1541/4885THRA 3654/4885THRB 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.